Vitrolife’s subsidiary in the U.S.A., Vitrolife, Inc, has together with Southwest Transplant Alliance and University of Texas been sued for compensation by relatives to a patient who diseased after a lung transplantation in 2010.
Vitrolife’s product for organ preservation (Perfadex) is claimed to have been used before the transplantation. Any number to the size of the claim has not been put forward.
Perfadex is an organ preservation solution that has been cleared by the FDA for the US market since 2001 and has to date been used in thousands of lung transplantations.
July 31, 2012
VITROLIFE AB (publ)
Queries should be addressed to:
Thomas Axelsson, CEO, phone 46 31 721 80 01
Mikael Engblom, CFO, phone 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 31, 2012 at 2:30 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.